Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Journey Medical Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage dermatology pharmaceutical company. The company’s Form 8-K reports cover financial results, corporate updates, Emrosi commercialization disclosures, pharmacy benefit coverage developments, and material agreements tied to its capital and operating structure.
DERM filings also include proxy materials for annual stockholder matters, including director elections and auditor ratification. Capital-structure disclosures include a term loan credit agreement amendment, an at-the-market common stock sales agreement under a Form S-3 registration statement, Nasdaq Capital Market common stock registration details, and emerging growth company status.
Journey Medical Corporation reported Q1 2026 revenue of $15.9 million, up 21% from Q1 2025, driven mainly by Emrosi sales of $6.3 million after its recent launch. Qbrexza and Accutane declined modestly, and foam franchise and legacy products fell more sharply due to competition.
The company narrowed its net loss to $2.2 million, or $(0.08) per share, compared with a $4.1 million loss a year earlier, helped by higher sales and stable operating costs. Cash and cash equivalents rose to $27.2 million, aided by positive operating cash flow of $2.9 million in the quarter.
Journey carries a $25.0 million term loan that bears interest at three‑month SOFR plus 7.75%, with principal payments scheduled to begin in February 2027. Despite improved results, management states that recurring and historical losses create substantial doubt about the company’s ability to continue as a going concern over the next twelve months.
Journey Medical Corporation reported strong top-line growth for the first quarter ended March 31, 2026. Total revenue rose 21% year-over-year to $15.96 million, driven largely by Emrosi®, which contributed $6.3 million in revenue as its prescription demand and payer coverage expanded.
The company still posted a GAAP net loss of $2.23 million, but this improved from a $4.07 million loss a year earlier. Loss per basic and diluted share narrowed to $(0.08) from $(0.18). Operating loss declined to $1.49 million from $3.32 million, reflecting better operating leverage from higher sales and disciplined spending.
On a non-GAAP basis, Adjusted EBITDA turned positive at $0.62 million, compared with a $(0.94) million Adjusted EBITDA loss in the prior-year quarter. Cash and cash equivalents increased to $27.22 million from $24.09 million at December 31, 2025, supporting management’s view that the company is well-positioned to continue executing its dermatology-focused growth strategy.
Journey Medical Corporation has issued its 2026 proxy statement for a virtual Annual Meeting on June 24, 2026 at 11:00 a.m. Eastern Time. Stockholders will vote on electing six directors for one-year terms and ratifying KPMG LLP as independent auditor for the year ending December 31, 2026.
The record date is April 28, 2026, with 21,346,446 shares of common stock and 6,000,000 shares of Class A common stock entitled to vote; each Class A share carries 3.91 votes. Directors, executive officers and 5% holders collectively beneficially own about 50.60% of outstanding common stock. The filing also details executive employment agreements, 2025 compensation and equity awards, director pay, audit fees, and governance policies including an insider trading policy and clawback policy.
Journey Medical Corp reports institutional ownership disclosure by Vanguard Capital Management. Vanguard Capital Management reports beneficial ownership of 1,206,395 shares of Common Stock, representing 5.65% of the class. The filing states Vanguard has sole dispositive power over 1,206,395 shares and sole voting power for 124,315 shares. The filing notes this reflects holdings across Vanguard affiliates and funds, per SEC Release No. 34-39538.
Journey Medical Corp Chief Operating Officer Ramsey Alloush received new equity awards as part of compensation. On April 22, 2026, he was granted 46,863 restricted stock units that vest in three equal installments on April 22 of 2027, 2028, and 2029. He also received stock options for 62,795 shares of common stock at an exercise price of $5.04 per share, vesting on the same dates. After these awards, he directly owns 598,543 shares of common stock, including restricted stock units. The options expire on April 22, 2036, giving him long-term upside exposure tied to the company’s share price.
Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation. On April 22, 2026, he was granted 28,907 restricted stock units that vest in three annual installments from April 2027 through April 2029. He also received 41,860 stock options with an exercise price of $5.04 per share, vesting annually over the same three-year period and expiring in 2036. After these awards, he directly holds 261,371 shares of common stock, and has 41,860 options outstanding.
Journey Medical Corp reported that President & CEO Claude Maraoui received new equity awards as part of his compensation. On April 22, 2026, he was granted 49,277 restricted stock units that vest in three equal annual installments from 2027 through 2029.
He was also granted stock options for 82,915 shares at an exercise price of $5.04 per share, vesting on the same 2027–2029 schedule and expiring in 2036. Following these grants, Maraoui directly holds 2,435,990 shares of common stock and 82,915 options.
Journey Medical Corporation reported a major expansion in payer coverage for Emrosi™, its oral treatment for inflammatory lesions of rosacea in adults. After securing a contract with a third major group purchasing organization, Emrosi™ payer access increased from approximately 100 million to over 150 million commercial lives as of April 1, 2026.
The company states that about 85% of all commercial lives in the United States now have access to Emrosi™, which it expects will support growth in total prescriptions, broader formulary adoption through 2026 and beyond, and reduced reliance on its co-pay bridging program.
Journey Medical Corp ownership disclosure: Wasatch Advisors reports beneficial ownership of 2,133,370 shares, representing 10.0% of the common stock as reported 03/31/2026. The filing shows sole voting power for 1,979,366 shares and sole dispositive power for 2,133,370 shares.
Journey Medical Corporation outlines its dermatology-focused business in its annual report, highlighting a portfolio of eight FDA‑approved prescription products and several legacy brands. The company concentrates on acne, rosacea, hyperhidrosis, fungal infections, pruritus and wound care, selling mainly through specialty pharmacies and distributors in the U.S.
In 2024 the FDA approved Emrosi, a low‑dose oral minocycline for rosacea, which launched commercially in 2025 and is protected by patents through 2039. Journey also markets Qbrexza, Amzeeq, Zilxi and Accutane under multiple in‑license and acquisition agreements that include milestones and royalties.
The report emphasizes growth via additional product licenses and acquisitions, notes new out‑licensing deals in Asia, and describes reliance on third‑party manufacturers and partners. It also details extensive intellectual property, regulatory and healthcare compliance frameworks, and key risks such as generic competition, pricing pressure, and Fortress Biotech’s voting control.